Journey Medical (DERM) Q4 2025 earnings review
Emrosi Launch Boosts Full-Year Results, But Sequential Growth Hits a Wall
Journey Medical's FY25 results showcase the transformative impact of its Emrosi launch, driving total revenues up 10% YoY to $61.9M and pushing Adjusted EBITDA into positive territory at $2.9M. However, peeling back the full-year numbers reveals a concerning Q4 reality. By deducting Q1-Q3 reported figures, we derive that Q4 total revenue contracted sequentially to ~$16.1M (down from $17.6M in Q3). More alarmingly, derived Q4 Emrosi sales flatlined at ~$4.9M, showing zero sequential growth from Q3. Management's narrative of 'rapid uptake' is heavily contradicted by this Q4 stagnation, especially as legacy Accutane sales continue to erode.
🐂 Bull Case
Gross margins improved significantly to 66.2% for the year, up from 62.8%. The product mix shift toward higher-margin Emrosi and Qbrexza is working as intended, proving the underlying unit economics of the new portfolio.
Emrosi finished the year with over 100 million U.S. commercial lives covered, up from 54 million in May. This broad access removes major friction points for prescribing dermatologists.
🐻 Bear Case
Despite achieving 53,000 total prescriptions for the year, derived Q4 Emrosi revenue was roughly $4.9M—flat compared to Q3. If the flagship growth driver is already plateauing sequentially in its third full quarter, the path to the stated $200M peak sales target is in jeopardy.
Accutane revenue declined by $6.5M in FY25 due to fierce generic competition. This massive headwind offsets a large portion of Emrosi's gains and forces the new drug to carry the entire weight of company growth.
⚖️ Verdict: 🔴
Bearish. While the headline YoY FY25 numbers look solid and profitability improved, the derived Q4 data points to a stalled launch for Emrosi and sequential top-line contraction. Without forward guidance to reassure markets, the flatlining of the primary growth engine is a major red flag.
Key Themes
Data Contradicts Narrative: Emrosi's Hidden Q4 Stall
Management's press release highlights 'rapid uptake' and 'strong prescription momentum' for Emrosi. However, analyzing the data tells a different story. FY25 Emrosi revenue was $14.7M. From prior earnings, we know Q1-Q3 cumulative Emrosi revenue was $9.8M ($2.1M + $2.8M + $4.9M). This means Q4 Emrosi revenue was exactly $4.9M, representing 0% sequential growth. A newly launched drug flatlining in its third full quarter suggests severe gross-to-net challenges, a failure to expand prescriber depth, or over-reliance on co-pay assistance programs.
Structural Gross Margin Improvements
The pivot toward Emrosi (40 mg Minocycline Hydrochloride Modified-Release) and Qbrexza is structurally improving the company's profitability profile. Gross margin expanded 340 basis points YoY to 66.2%. Because Emrosi is relatively cheap to manufacture, every incremental dollar of revenue disproportionately benefits the bottom line, which is how the company achieved $2.9M in Adjusted EBITDA despite overall revenue growing only 10%.
Accutane Generic Cannibalization
The base business remains a leaky bucket. Accutane revenue dropped by $6.5M in FY25. During previous quarters, management expressed hope that this decline was 'stabilizing.' However, the full-year drop indicates that generic competition continues to exert severe pricing and volume pressure on the legacy portfolio.
Commercial Lives and Payer Access Secured
A key bottleneck to early launch success was securing formulary access to transition patients off margin-crushing co-pay programs. Management secured payer access to over 100 million U.S. commercial lives by year-end. If they can convert these covered lives into recognized revenue (improving the gross-to-net ratio), it could reignite Emrosi's stalled sequential growth in early 2026.
Gross-to-Net Revenue Conversion Delays
While 53,000 total prescriptions were filled for Emrosi in FY25, translating those scripts into net revenue remains a challenge. The divergence between high script volume and flat Q4 revenue suggests the company is still heavily subsidizing patients via co-pay assistance while waiting for downstream health plans to update their formularies.
Other KPIs
Up 10% from $40.2M in FY24. This increase was expected and is tied directly to the commercialization activities and sales infrastructure required for the Emrosi launch. Importantly, SG&A growth (10%) perfectly matched revenue growth (10%), indicating management is maintaining expense discipline and not letting cost structures bloat.
Increased from $20.3M at the end of FY24 and essentially flat compared to $24.9M at the end of Q3. The stabilization of cash burn is a positive signal, proving the company can fund its current operations without immediate dilutive capital raises.
More than doubled from $13.0M at the end of FY24. This massive improvement provides a necessary liquidity buffer as the company navigates the delayed payment cycles associated with a new drug launch.
Guidance
Stable. The company explicitly refrained from providing quantitative forward-looking guidance for FY26 in the press release, instead relying on qualitative statements about remaining 'well-positioned' and driving 'solid revenue growth.' The lack of concrete targets for Emrosi's second year on the market may frustrate investors looking for visibility.
Key Questions
Emrosi Sequential Plateau
Based on the reported full-year figures, Q4 Emrosi revenue appears to be $4.9 million, completely flat compared to Q3. Why did sequential revenue growth stall, and is this a function of lower script volume, or worsening gross-to-net dynamics?
Core Portfolio Contraction
With Q4 total revenue at ~$16.1M and Emrosi contributing ~$4.9M, the core portfolio generated roughly $11.2M in Q4, down from $12.7M in Q3. Has the Accutane decline accelerated again, or is there another legacy product facing new headwinds?
Gross-to-Net Timeline
You now have over 100 million commercial lives covered. When do you expect this access to meaningfully improve the net revenue per script and reduce reliance on co-pay assistance?
Prescriber Depth
In previous quarters, you successfully acquired trial prescribers for Emrosi. What percentage of your 2025 prescribers are writing deep, recurring volume versus single-trial scripts?